Bausch & Lomb Corp

BLCO

Explore Our Financial Data > Companies > Bausch & Lomb Corp
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BLCO
CIK0001860742
SIC3851
SectorManufacturing
Industry CategoryMedical Equipment
Industry GroupOphthalmic Goods

Contact

Address520 APPLEWOOD CRESCENT, VAUGHAN, A6, L4K 4B4
Website bausch.com
Phone908-541-5456
CEOJoseph C. Papa
Employees12,500

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$4.98 billion
Pre-Tax Income$-340.00 million
Net Income$-296.00 million
Net Income to Common$-305.00 million
EPS$-0.86
View All
Balance Sheet
Cash$310.00 million
Assets$13.83 billion
Liabilities$7.33 billion
Common Equity$6.43 billion
Liabilities & Equity$13.83 billion
View All
Cash Flow Statement
Net Income$-296.00 million
Cash From Operating Activities$169.00 million
Cash From Investing Activities$-452.00 million
Cash From Financing Activities$255.00 million
Change in Cash$-18.00 million
View All
Calculations
NOPAT$61.60 million
EBITDA$603.00 million
Price to EarningsN/A
Price to Book$0.94
ROE-4.50%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

VAUGHAN, Ontario, December 12, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First

Article Link

Why Bausch + Lomb (BLCO) Stock Is Trading Up Today

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.2% in the morning session after Citigroup upgraded its rating on the company's shares to Buy from Neutral and raised its price target. The investment bank adjusted its price forecast to $20, up from the previous target of $16. This change in rating suggested a more positive outlook from the bank regarding the eye health company's future stock performance.

Article Link

3 Healthcare Stocks We Think Twice About

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 13.5%, nearly mirrorring the S&P 500.

Article Link

Wall Street Cautious on ​Bausch + Lomb Corporation (BLCO), Here’s Why

​Bausch + Lomb Corporation (NYSE:BLCO) is one of the Best Up and Coming Canadian Stocks to Buy. Wall Street has a cautious outlook on the stock despite an 8.59% increase in share price during the month. ​On November 13, Bausch + Lomb Corporation (NYSE:BLCO) highlighted its growth strategy at investor day. The management noted they […]

Article Link

BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point?

One fund just made a bold move on an eye-care giant—here’s why it may signal a deeper shift in the company’s long-term trajectory.

Article Link